Canadian scientists assert that curcuminoids with omega-3 fatty acids can increase the bioavailability of active ingredients by as much as 40% and lower the risk of adverse events compared to alternative supplements.
Sabinsa has secured Novel Food approval for its patented curcuminoid metabolite ingredient C3 Reduct, giving supplement manufacturers in Europe a bioavailable curcuminoid option.